Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2022 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera und ReveraGen starten schrittweise NDA-Einreichung bei der FDA für Vamorolone zur Behandlung von Duchenne-Muskeldystrophie

Pratteln, Schweiz, 29. März 2022 - Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. (US: privat) geben den Beginn der schrittweisen Einreichung eines Zulassungsantrags (NDA, new drug...
March 29, 2022 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

Pratteln, Switzerland, March 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce the initiation of a rolling new drug application (NDA) submission to...
March 15, 2022 02:05 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera und ReveraGen präsentieren Daten zur Wirksamkeit und Verträglichkeit von Vamorolone an der 2022 MDA Konferenz

Pratteln, Schweiz, und Rockville, MD, USA, 15. März , 2022 - Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. geben bekannt, dass sie an der 2022 Muscular Dystrophy Association (MDA)...
March 15, 2022 02:05 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference

Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with...
March 15, 2022 02:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera vollzieht ordentliche Kapitalerhöhung zur Schaffung eigener Aktien für künftige Finanzierungen

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 15. März...
March 15, 2022 02:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland,...
March 11, 2022 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera gibt vorläufige Finanzergebnisse für 2021 bekannt und erhöht das Aktienkapital zur Schaffung eigener Aktien für künftige Finanzierungen

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc-Mitteilung gemäss Art. 53 KR Start der Einreichung des...
March 11, 2022 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Initiation of rolling...
February 28, 2022 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera unterzeichnet Gentherapie-Vereinbarung mit SEAL Therapeutics

Pratteln, Schweiz, 28. Februar 2022 - Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer Vereinbarung mit SEAL Therapeutics für einen Gentherapieansatz zur Behandlung von kongenitaler...
February 28, 2022 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Signs Gene Therapy Agreement with SEAL Therapeutics

Pratteln, Switzerland, February 28, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular...